11 Result(s)
-
Article
Open AccessPIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer
Novel drugs like Abiraterone or Enzalutamide, which target androgen receptor (AR) signaling to improve androgen deprivation therapy (ADT), have been developed during the past years. However, the application of...
-
Article
Open AccessEpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205
Expression of epithelial cell adhesion molecule (EpCAM) is deregulated in epithelial malignancies. Beside its role in cell adhesion, EpCAM acts as signalling molecule with tumour-promoting functions. Thus, EpC...
-
Article
Long-term biochemical evaluation of the androgen receptor pathway in males with disorders of sex development
Disorders of sex (DSD) development represent a serious condition. Most of the underlying mechanisms remain unclear. Disturbances within the androgen receptor (AR) pathway frequently account for 46 XY-DSDs. The...
-
Article
Open AccessInsulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer
Insulin-like growth factor (IGF) and insulin (INS) proteins regulate key cellular functions through a complex interacting multi-component molecular network, known as the IGF/INS axis. We describe how dynamic a...
-
Article
Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia
The development of human benign prostatic hyperplasia (BPH) clearly requires a combination of testicular androgens and the ageing process. Although the role of androgens as the causative factor for human beni...
-
Article
Open AccessAndrogen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells
Interactions between polypeptide growth factors and the androgen receptor (AR) are important for regulation of cellular events in carcinoma of the prostate. Basic fibroblast growth factor (bFGF), the prototype...
-
Article
Open AccessSwitch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we establish...
-
Article
Interleukin 1β mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells
Proliferative and secretory responses in androgen-sensitive prostate cancer LNCaP cells are regulated by steroid and peptide hormones and by differentiation-promoting substances. In the present study, we evalu...
-
Article
Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas
We previously detected elevated transforming growth factor beta-1 (TGF-beta1) serum levels in patients with invasive bladder carcinomas. In this study, we therefore investigated whether elevated serum levels c...
-
Article
Activation of the androgen receptor by polypeptide growth factors and cellular regulators
The polypeptide growth factors insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), and transforming growth factor-α (TGF-α); second-messenger cyclic adenosine monophosphate (cAMP); protein kin...
-
Article
Androgen signal transduction and prostatic carcinoma
In the prostate, androgen action affects the growth of the gland, its morphology, and regulation of protein expression. Endocrine therapy of non-organ-confined tumors is based on the androgen dependence of the...
